Visual outcomes of polypoidal choroidal vasculopathy with prompt or deferred treatments or without treatments

Visual outcomes of polypoidal choroidal vasculopathy with prompt or deferred treatments or without treatments - Polypoidal choroidal vasculopathy with or without treatments

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031352

Enrollment

Registered

2018-03-01

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polypoidal choroidal vasculopathy

Interventions

photodynamic therapy (PDT) anti-vascular endothelial growth factor (VEGF) therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients, who consulted a ophthalmologist in Nagoya City University Hospital between April 2009 and March 2017 and were diagnosed as polypoidal choroidal vasculopathy (PCV) with a baseline best corrected visual acuity (BCVA) of 20/200 or better

Exclusion criteria

Exclusion criteria: 1. past history of photocoagulation or photodynamic therapy or anti-vascular endothelial growth factor therapy 2. presence of other macular diseases 3. presence of uveitis 4. past history of vitrectomy 5. hazy media causing difficulties in fun dus examinations 6. pregnant or planned for pregnancy 7. undergone intraocular surgeries within the previous 6 months 8. judged by the investigator to be ineligible for other reasons

Design outcomes

Primary

Measure	Time frame
(1) Changes in best-corrected visual acuity (2) Timing and the number of treatments	—

Countries

Japan

Contacts

Public ContactTsutomu Yasukawa

Nagoya City University Graduate School of Medical Sciences Department of Ophthalmology and Visual Science

yasukawa@med.nagoya-cu.ac.jp052-853-8251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026